Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Next Previous
Trial Profile

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golcadomide (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOLSEEK-3
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 14 May 2025 Planned End Date changed from 31 Aug 2029 to 10 Oct 2030.
  • 14 May 2025 Planned primary completion date changed from 21 Dec 2025 to 30 Jan 2027.
  • 08 Dec 2024 Study design presented at the 66th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top